Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children80610.24287/1726-1708-2023-22-4-186-205DIAGNOSTIC GUIDELINESДИАГНОСТИЧЕСКИЕ РЕКОМЕНДАЦИИGuidelines for the use of flow cell sorting in diagnosis and monitoring of acute leukemiaРекомендации по применению проточной сортировки клеток в диагностике и мониторинге острых лейкозовSemchenkovaA. A.СемченковаА. А.
Russian Federation

Alexandra A. Semchenkova, a researcher at the Leukemia Immunophenotyping Laboratory

1 Samory Mashela St., Moscow 117997

Семченкова Александра Александровна, научный  сотрудник лаборатории иммунофенотипирования гемобластозов

117997, Москва, ул. Саморы Машела, 1

semalex94@mail.ruIllarionovaO. I.ИлларионоваО. И.
Russian Federation

Moscow

Москва

DeminaI. A.ДёминаИ. А.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0002-3450-0498MikhailovaE. V.МихайловаЕ. В.
Russian Federation

Moscow

Москва

ZerkalenkovaE. A.ЗеркаленковаЕ. А.
Russian Federation

Moscow

Москва

ZakharovaE. S.ЗахароваЕ. С.
Russian Federation

Moscow

Москва

BrilliantovaV. V.БриллиантоваВ. В.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0002-9300-198XKarachunskiyA. I.КарачунскийА. И.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0003-1735-0093MaschanM. A.МасчанМ. А.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0002-2322-5734NovichkovaG. A.НовичковаГ. А.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0002-0889-6986PopovA. M.ПоповА. М.
Russian Federation

Moscow

Москва

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России201220232241862050501202405012024Copyright ©; 2023, «D. Rogachev NMRCPHOI»Copyright ©; 2023, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2023«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/806

Flow cell sorting is an advanced laboratory technique that combines the analytical capabilities of flow cytometry with the ability to isolate pure cell populations from heterogeneous samples. It has tremendous potential both for fundamental research and laboratory diagnosis. For example, the combination of cell sorting and molecular genetic studies can be used to clarify ambiguous results of acute leukemia immunophenotyping obtained both at diagnosis and during minimal residual disease monitoring. These guidelines are based on years of experience in incorporating cell sorting into the diagnostic and monitoring processes at the Leukemia Immunophenotyping Laboratory of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. They include methods used for the confirmation of flow cytometry data depending on the type of leukemia, the stage of a flow cytometry assay and previous therapy. They also describe cell sorting algorithms for disease diagnosis and the specifics of sample preparation for cell sorting in different molecular genetic studies.

Клеточная сортировка – высокотехнологичный лабораторный метод, сочетающий в себе аналитические возможности проточной цитометрии с функцией выделения чистых клеточных популяций из гетерогенного образца. Он обладает огромным потенциалом для применения не только в фундаментальных исследованиях, но и в различных областях лабораторной диагностики. В частности, сочетание сортировки клеток с последующими молекулярногенетическими исследованиями можно использовать для уточнения неоднозначных результатов иммунофенотипирования острых лейкозов как при первичной диагностике, так и в мониторинге минимальной остаточной болезни. Данные рекомендации основаны на опыте включения сортировки в диагностический и мониторинговый процесс лаборатории иммунофенотипирования гемобластозов НМИЦ ДГОИ им. Дмитрия Рогачева. В них описаны методики, используемые для подтверждения цитометрических данных в зависимости от типа лейкоза, этапа цитометрического исследования, предшествующей терапии, а также алгоритмы применения сортировки клеток в диагностическом поиске и нюансы пробоподготовки для сортировки клеток для различных молекулярно-генетических исследований.

acute leukemiaflow cell sortingimmunophenotypingminimal residual diseaseострый лейкозпроточная сортировкаиммунофенотипированиеминимальная остаточная болезнь1. Robinson J.P., Ostafe R., Iyengar S.N., Rajwa B., Fischer R. Flow Cytometry: The Next Revolution. Cells 2023; 12 (14): 1875.Robinson J.P., Ostafe R., Iyengar S.N., Rajwa B., Fischer R. Flow Cytometry: The Next Revolution. Cells 2023; 12 (14): 1875.2. Alexander T.B., Gu Z., Iacobucci I., Dickerson K., Choi J.K., Xu B., et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature 2018; 562 (7727): 373–9.Alexander T.B., Gu Z., Iacobucci I., Dickerson K., Choi J.K., Xu B., et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature 2018; 562 (7727): 373–9.3. Rabilloud T., Potier D., Pankaew S., Nozais M., Loosveld M., Payet-Bornet D. Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy. Nat Commun 2021; 12 (1): 865.Rabilloud T., Potier D., Pankaew S., Nozais M., Loosveld M., Payet-Bornet D. Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy. Nat Commun 2021; 12 (1): 865.4. Bueno C., Barrera S., Bataller A., Ortiz-Maldonado V., Elliot N., O'Byrne S., et al. CD34+ CD19– CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. Blood 2022; 140 (1): 38–44.Bueno C., Barrera S., Bataller A., Ortiz-Maldonado V., Elliot N., O'Byrne S., et al. CD34+ CD19– CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. Blood 2022; 140 (1): 38–44.5. Kotrova M., Musilova A., Stuchly J., Fiser K., Starkova J., Mejstrikova E., et al. Distinct bilineal leukemia immunophenotypes are not genetically determined. Blood 2016; 128 (18): 2263–6.Kotrova M., Musilova A., Stuchly J., Fiser K., Starkova J., Mejstrikova E., et al. Distinct bilineal leukemia immunophenotypes are not genetically determined. Blood 2016; 128 (18): 2263–6.6. Reichel J., Chadburn A., Rubinstein P.G., Giulino-Roth L., Tam W., Liu Y., et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 2015; 125 (7): 1061–72.Reichel J., Chadburn A., Rubinstein P.G., Giulino-Roth L., Tam W., Liu Y., et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 2015; 125 (7): 1061–72.7. Fromm J.R., Thomas A., Wood B.L. Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. Am J Pathol 2017; 187 (2): 304–17.Fromm J.R., Thomas A., Wood B.L. Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. Am J Pathol 2017; 187 (2): 304–17.8. Fromm J.R., Kussick S.J., Wood B.L. Identification and purification of classical Hodgkin cells from lymph nodes by flow cytometry and flow cytometric cell sorting. Am J Clin Pathol 2006; 126 (5): 764–80.Fromm J.R., Kussick S.J., Wood B.L. Identification and purification of classical Hodgkin cells from lymph nodes by flow cytometry and flow cytometric cell sorting. Am J Clin Pathol 2006; 126 (5): 764–80.9. Obro N.F., Madsen H.O., Ryder L.P., Andersen M.K., Schmiegelow K., Marquart H.V. Approaches for cytogenetic and molecular analyses of small flow-sorted cell populations from childhood leukemia bone marrow samples. J Immunol Methods 2011; 369 (1–2): 69–73.Obro N.F., Madsen H.O., Ryder L.P., Andersen M.K., Schmiegelow K., Marquart H.V. Approaches for cytogenetic and molecular analyses of small flow-sorted cell populations from childhood leukemia bone marrow samples. J Immunol Methods 2011; 369 (1–2): 69–73.10. Semchenkova A., Brilliantova V., Shelikhova L., Zhogov V., Illarionova O., Mikhailova E., et al. Chimerism evaluation in measurable residual disease-suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Cytometry B Clin Cytom 2021; 100 (5): 568–73.Semchenkova A., Brilliantova V., Shelikhova L., Zhogov V., Illarionova O., Mikhailova E., et al. Chimerism evaluation in measurable residual disease-suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Cytometry B Clin Cytom 2021; 100 (5): 568–73.11. Semchenkova A., Zhogov V., Zakharova E., Mikhailova E., Illarionova O., Larin S., et al. Flow cell sorting followed by PCR-based clonality testing may assist in questionable diagnosis and monitoring of acute lymphoblastic leukemia. Int J Lab Hematol 2023; 45 (4): 506–15.Semchenkova A., Zhogov V., Zakharova E., Mikhailova E., Illarionova O., Larin S., et al. Flow cell sorting followed by PCR-based clonality testing may assist in questionable diagnosis and monitoring of acute lymphoblastic leukemia. Int J Lab Hematol 2023; 45 (4): 506–15.12. Semchenkova A., Zerkalenkova E., Demina I., Kashpor S., Volchkov E., Zakharova E., et al. Recognizing Minor Leukemic Populations with Monocytic Features in Mixed-Phenotype Acute Leukemia by Flow Cell Sorting Followed by Cytogenetic and Molecular Studies: Report of Five Exemplary Cases. Int J Mol Sci 2023; 24 (6): 5260.Semchenkova A., Zerkalenkova E., Demina I., Kashpor S., Volchkov E., Zakharova E., et al. Recognizing Minor Leukemic Populations with Monocytic Features in Mixed-Phenotype Acute Leukemia by Flow Cell Sorting Followed by Cytogenetic and Molecular Studies: Report of Five Exemplary Cases. Int J Mol Sci 2023; 24 (6): 5260.13. Obro N.F., Ryder L.P., Madsen H.O., Andersen M.K., Lausen B., Hasle H., et al. Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods. Haematologica 2012; 97 (1): 137–41.Obro N.F., Ryder L.P., Madsen H.O., Andersen M.K., Lausen B., Hasle H., et al. Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods. Haematologica 2012; 97 (1): 137–41.14. DiGiuseppe J.A., Wood B.L. Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lym phoma. Cytometry B Clin Cytom 2019; 96 (4): 256–65.DiGiuseppe J.A., Wood B.L. Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lym phoma. Cytometry B Clin Cytom 2019; 96 (4): 256–65.15. Borowitz M.J., Pullen D.J., Winick N., Martin P.L., Bowman W.P., Camitta B. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group. Cytometry B Clin Cytom 2005; 68 (1): 18–24.Borowitz M.J., Pullen D.J., Winick N., Martin P.L., Bowman W.P., Camitta B. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group. Cytometry B Clin Cytom 2005; 68 (1): 18–24.16. Dworzak M.N., Gaipa G., Schumich A., Maglia O., Ratei R., Veltroni M., et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. Cytometry B Clin Cytom 2010; 78 (3): 147–53.Dworzak M.N., Gaipa G., Schumich A., Maglia O., Ratei R., Veltroni M., et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. Cytometry B Clin Cytom 2010; 78 (3): 147–53.17. Semchenkova A., Zhogov V., Rudneva A., Potapenko L., Plyasunova S., Miakova N., et al. Immune reconstitution following rituximab-based immunochemotherapy in pediatric patients with B-cell non-Hodgkin lymphomas. Leuk Lymphoma 2022; 63 (1): 217–21.Semchenkova A., Zhogov V., Rudneva A., Potapenko L., Plyasunova S., Miakova N., et al. Immune reconstitution following rituximab-based immunochemotherapy in pediatric patients with B-cell non-Hodgkin lymphomas. Leuk Lymphoma 2022; 63 (1): 217–21.18. Mikhailova E., Gluhanyuk E., Illarionova O., Zerkalenkova E., Kashpor S., Miakova N., et al. Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, who have been treated with Blinatumomab. Haematologica 2021; 106 (7): 2009–12.Mikhailova E., Gluhanyuk E., Illarionova O., Zerkalenkova E., Kashpor S., Miakova N., et al. Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, who have been treated with Blinatumomab. Haematologica 2021; 106 (7): 2009–12.19. Попов А.М., Вержбицкая Т.Ю., Мовчан Л.В., Дёмина И.А., Михайлова Е.В., Семченкова А.А. и др. Диагностическое иммунофенотипирование острых лейкозов. Рекомендации российско-белорусской кооперативной группы по диагностике острых лейкозов у детей. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2023; 22 (1): 165–77. DOI: 10.24287/1726-1708-2023-22-1-165-177Попов А.М., Вержбицкая Т.Ю., Мовчан Л.В., Дёмина И.А., Михайлова Е.В., Семченкова А.А. и др. Диагностическое иммунофенотипирование острых лейкозов. Рекомендации российско-белорусской кооперативной группы по диагностике острых лейкозов у детей. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2023; 22 (1): 165–77. DOI: 10.24287/1726-1708-2023-22-1-165-17720. Попов А.М., Михайлова Е.В., Вержбицкая Т.Ю., Мовчан Л.В., Пермикин Ж.В., Шман Т.В. и др. Определение минимальной остаточной болезни при В-линейном остром лимфобластном лейкозе методом проточной цитометрии. Рекомендации российско-белорусской кооперативной группы по диагностике острых лейкозов у детей. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2023; 22 (3): 199–209. DOI: 10.24287/1726-1708-2023-22-3-199-209Попов А.М., Михайлова Е.В., Вержбицкая Т.Ю., Мовчан Л.В., Пермикин Ж.В., Шман Т.В. и др. Определение минимальной остаточной болезни при В-линейном остром лимфобластном лейкозе методом проточной цитометрии. Рекомендации российско-белорусской кооперативной группы по диагностике острых лейкозов у детей. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2023; 22 (3): 199–209. DOI: 10.24287/1726-1708-2023-22-3-199-20921. Михайлова Е.В., Илларионова О.И., Масчан М.А., Новичкова Г.А., Карачунский А.И., Попов А.М. Рекомендации по определению минимальной остаточной болезни методом проточной цитометрии при остром В-лимфобластном лейкозе в условиях применения CD19-направленной терапии. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2023; 22 (2): 175–84. DOI: 10.24287/1726-1708-2023-22-2-175-184Михайлова Е.В., Илларионова О.И., Масчан М.А., Новичкова Г.А., Карачунский А.И., Попов А.М. Рекомендации по определению минимальной остаточной болезни методом проточной цитометрии при остром В-лимфобластном лейкозе в условиях применения CD19-направленной терапии. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2023; 22 (2): 175–84. DOI: 10.24287/1726-1708-2023-22-2-175-18422. Цаур Г.А., Ольшанская Ю.В., Обухова Т.Н., Судариков А.Б., Лазарева О.В., Гиндина Т.Л. Цитогенетическая и молекулярно-генетическая диагностика онкогематологических заболеваний: позиция Организации молекулярных генетиков в онкологии и онкогематологии. Гематология и трансфузиология 2023; 68 (1): 129–43. DOI: 10.35754/0234-5730-2023-68-1-129-143Цаур Г.А., Ольшанская Ю.В., Обухова Т.Н., Судариков А.Б., Лазарева О.В., Гиндина Т.Л. Цитогенетическая и молекулярно-генетическая диагностика онкогематологических заболеваний: позиция Организации молекулярных генетиков в онкологии и онкогематологии. Гематология и трансфузиология 2023; 68 (1): 129–43. DOI: 10.35754/0234-5730-2023-68-1-129-14323. Van Dongen J.J., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13 (12): 1901–28.Van Dongen J.J., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13 (12): 1901–28.24. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia 2003; 17 (12): 2318–57.Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia 2003; 17 (12): 2318–57.25. Tsaur G., Popov A., Riger T., Kustanovich A., Solodovnikov A., Shorikov E., et al. Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol. Br J Haematol 2021; 193 (6): 1151–6.Tsaur G., Popov A., Riger T., Kustanovich A., Solodovnikov A., Shorikov E., et al. Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol. Br J Haematol 2021; 193 (6): 1151–6.26. Popov A., Tsaur G., Verzhbitskaya T., Riger T., Permikin Z., Demina A., et al. Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements. Br J Haematol 2023; 201 (3): 510–9.Popov A., Tsaur G., Verzhbitskaya T., Riger T., Permikin Z., Demina A., et al. Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements. Br J Haematol 2023; 201 (3): 510–9.27. Langerak A.W., Groenen P.J., Bruggemann M., Beldjord K., Bellan C., Bonello L., et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 2012; 26 (10): 2159–71.Langerak A.W., Groenen P.J., Bruggemann M., Beldjord K., Bellan C., Bonello L., et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 2012; 26 (10): 2159–71.28. Scheijen B., Meijers R.W.J., Rijntjes J., van der Klift M.Y., Mobs M., Steinhilber J., et al. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS. Leukemia 2019; 33 (9): 2227–40.Scheijen B., Meijers R.W.J., Rijntjes J., van der Klift M.Y., Mobs M., Steinhilber J., et al. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS. Leukemia 2019; 33 (9): 2227–40.29. Gendzekhadze K., Gaidulis L., Senitzer D. Chimerism testing by quantitative PCR using Indel markers. Methods Mol Biol 2013; 1034: 221–37.Gendzekhadze K., Gaidulis L., Senitzer D. Chimerism testing by quantitative PCR using Indel markers. Methods Mol Biol 2013; 1034: 221–37.30. Demina I., Zerkalenkova E., Semchenkova A., Volchkov E., Boychenko E., Prudnikova M., et al. Rare case of pediatric trilineal mixed-phenotype acute leukemia with t(11;19) (q23.3;p13)/KMT2A::ELL. Leuk Res 2023; 125: 107018.Demina I., Zerkalenkova E., Semchenkova A., Volchkov E., Boychenko E., Prudnikova M., et al. Rare case of pediatric trilineal mixed-phenotype acute leukemia with t(11;19) (q23.3;p13)/KMT2A::ELL. Leuk Res 2023; 125: 107018.31. Kolenova A., Maloney K.W., Hunger S.P. Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Crisis. J Pediatr Hematol Oncol 2016; 38 (6): e193–5.Kolenova A., Maloney K.W., Hunger S.P. Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Crisis. J Pediatr Hematol Oncol 2016; 38 (6): e193–5.32. Balducci E., Loosveld M., Rahal I., Boudjarane J., Alazard E., Missirian C., et al. Interphase FISH for BCR-ABL1 rearrangement on neutrophils: A decisive tool to discriminate a lymphoid blast crisis of chronic myeloid leukemia from a de novo BCR-ABL1 positive acute lymphoblastic leukemia. Hematol Oncol 2018; 36 (1): 344–8.Balducci E., Loosveld M., Rahal I., Boudjarane J., Alazard E., Missirian C., et al. Interphase FISH for BCR-ABL1 rearrangement on neutrophils: A decisive tool to discriminate a lymphoid blast crisis of chronic myeloid leukemia from a de novo BCR-ABL1 positive acute lymphoblastic leukemia. Hematol Oncol 2018; 36 (1): 344–8.33. Chen Z., Hu S., Wang S.A., Konopleva M., Tang Z., Xu J., et al. Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia. Leuk Lymphoma 2020; 61 (12): 2831–8.Chen Z., Hu S., Wang S.A., Konopleva M., Tang Z., Xu J., et al. Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia. Leuk Lymphoma 2020; 61 (12): 2831–8.34. Попов А.М., Вержбицкая Т.Ю., Фечина Л.Г., Шестопалов А.В., Плясунова С.А. Острые лейкозы: различия иммунофенотипа бластных клеток и их неопухолевых аналогов в костном мозге. Клиническая онкогематология 2016; 9 (3): 302–13.Попов А.М., Вержбицкая Т.Ю., Фечина Л.Г., Шестопалов А.В., Плясунова С.А. Острые лейкозы: различия иммунофенотипа бластных клеток и их неопухолевых аналогов в костном мозге. Клиническая онкогематология 2016; 9 (3): 302–13.35. Dorantes-Acosta E., Pelayo R. Lineage switching in acute leukemias: a consequence of stem cell plasticity? Bone Marrow Res 2012; 2012: 406796.Dorantes-Acosta E., Pelayo R. Lineage switching in acute leukemias: a consequence of stem cell plasticity? Bone Marrow Res 2012; 2012: 406796.36. Gardner R., Wu D., Cherian S., Fang M., Hanafi L.A., Finney O., et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 2016; 127 (20): 2406–10.Gardner R., Wu D., Cherian S., Fang M., Hanafi L.A., Finney O., et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 2016; 127 (20): 2406–10.37. Semchenkova A., Mikhailova E., Komkov A., Gaskova M., Abasov R., Matveev E., et al. Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy. Int J Mol Sci 2022; 23 (7): 4019.Semchenkova A., Mikhailova E., Komkov A., Gaskova M., Abasov R., Matveev E., et al. Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy. Int J Mol Sci 2022; 23 (7): 4019.38. Mikhailova E., Semchenkova A., Illarionova O., Kashpor S., Brilliantova V., Zakharova E., et al. Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease. Br J Haematol 2021; 193 (3): 602–12.Mikhailova E., Semchenkova A., Illarionova O., Kashpor S., Brilliantova V., Zakharova E., et al. Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease. Br J Haematol 2021; 193 (3): 602–12.39. Gaipa G., Basso G., Maglia O., Leoni V., Faini A., Cazzaniga G., et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia 2005; 19 (1): 49–56.Gaipa G., Basso G., Maglia O., Leoni V., Faini A., Cazzaniga G., et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia 2005; 19 (1): 49–56.40. Mikhailova E., Illarionova O., Shelikhova L., Zerkalenkova E., Molostova O., Olshanskaya Y., et al. Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)-expressing T cells. Haematologica 2022; 107 (4): 970–4.Mikhailova E., Illarionova O., Shelikhova L., Zerkalenkova E., Molostova O., Olshanskaya Y., et al. Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)-expressing T cells. Haematologica 2022; 107 (4): 970–4.41. Mejstrikova E., Klinger M., Markovic A., Zugmaier G., Locatelli F. CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab. Pediatr Blood Cancer 2021; 68 (12): e29323.Mejstrikova E., Klinger M., Markovic A., Zugmaier G., Locatelli F. CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab. Pediatr Blood Cancer 2021; 68 (12): e29323.42. Libert D., Yuan C.M., Masih K.E., Galera P., Salem D., Shalabi H., et al. Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy. Leukemia. 2020; 34 (11): 3064–9.Libert D., Yuan C.M., Masih K.E., Galera P., Salem D., Shalabi H., et al. Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy. Leukemia. 2020; 34 (11): 3064–9.43. Cherian S., Miller V., McCullouch V., Dougherty K., Fromm J.R., Wood B.L. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy. Cytometry B Clin Cytom 2018; 94 (1): 112–20.Cherian S., Miller V., McCullouch V., Dougherty K., Fromm J.R., Wood B.L. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy. Cytometry B Clin Cytom 2018; 94 (1): 112–20.44. Mikhailova E., Illarionova O., Komkov A., Zerkalenkova E., Mamedov I., Shelikhova L., et al. Reliable Flow-Cytometric Approach for Minimal Residual Disease Monitoring in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia after CD19-Targeted Therapy. Cancers (Basel) 2022; 14 (21): 5445.Mikhailova E., Illarionova O., Komkov A., Zerkalenkova E., Mamedov I., Shelikhova L., et al. Reliable Flow-Cytometric Approach for Minimal Residual Disease Monitoring in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia after CD19-Targeted Therapy. Cancers (Basel) 2022; 14 (21): 5445.45. Verbeek M.W.C., Buracchi C., Laqua A., Nierkens S., Sedek L., Flores-Montero J., et al. Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies – a EuroFlow study. Br J Haematol 2022; 197 (1): 76–81.Verbeek M.W.C., Buracchi C., Laqua A., Nierkens S., Sedek L., Flores-Montero J., et al. Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies – a EuroFlow study. Br J Haematol 2022; 197 (1): 76–81.46. Novakova M., Zaliova M., Fiser K., Vakrmanova B., Slamova L., Musilova A., et al. DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch. Haematologica 2021; 106 (8): 2066–75.Novakova M., Zaliova M., Fiser K., Vakrmanova B., Slamova L., Musilova A., et al. DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch. Haematologica 2021; 106 (8): 2066–75.47. Slamova L., Starkova J., Fronkova E., Zaliova M., Reznickova L., van Delft F.W., et al. CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage. Leukemia 2014; 28 (3): 609–20.Slamova L., Starkova J., Fronkova E., Zaliova M., Reznickova L., van Delft F.W., et al. CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage. Leukemia 2014; 28 (3): 609–20.48. Permikin Z., Popov A., Verzhbitskaya T., Riger T., Plekhanova O., Makarova O., et al. Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report. Leuk Res 2022; 112: 106758.Permikin Z., Popov A., Verzhbitskaya T., Riger T., Plekhanova O., Makarova O., et al. Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report. Leuk Res 2022; 112: 106758.49. Pemmaraju N., Kantarjian H., Jorgensen J.L., Jabbour E., Jain N., Thomas D., et al. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol 2017; 92 (3): 279–85.Pemmaraju N., Kantarjian H., Jorgensen J.L., Jabbour E., Jain N., Thomas D., et al. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol 2017; 92 (3): 279–85.50. Buchmann S., Schrappe M., Baruchel A., Biondi A., Borowitz M.J., Campbell M., et al. Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium. Blood 2022; 139 (12): 1785–93.Buchmann S., Schrappe M., Baruchel A., Biondi A., Borowitz M.J., Campbell M., et al. Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium. Blood 2022; 139 (12): 1785–93.51. Ali H., Salhotra A., Stein A.S., Nakamura R., Marcucci G., Forman S.J., et al. Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT. Leuk Res 2021; 104: 106579.Ali H., Salhotra A., Stein A.S., Nakamura R., Marcucci G., Forman S.J., et al. Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT. Leuk Res 2021; 104: 106579.52. Keating A.K., Gossai N., Phillips C.L., Maloney K., Campbell K., Doan A., et al. Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. Blood Adv 2019; 3 (13): 1926–9.Keating A.K., Gossai N., Phillips C.L., Maloney K., Campbell K., Doan A., et al. Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. Blood Adv 2019; 3 (13): 1926–9.53. Viardot A., Locatelli F., Stieglmaier J., Zaman F., Jabbour E. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Ann Hematol 2020; 99 (10): 2215–29.Viardot A., Locatelli F., Stieglmaier J., Zaman F., Jabbour E. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Ann Hematol 2020; 99 (10): 2215–29.54. Queudeville M., Ebinger M. Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review). J Clin Med 2021; 10 (12): 2544.Queudeville M., Ebinger M. Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review). J Clin Med 2021; 10 (12): 2544.55. Mikhailova E., Roumiantseva J., Illarionova O., Lagoyko S., Miakova N., Zerkalenkova E., et al. Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children. Br J Haematol 2022; 196 (1): e6–9.Mikhailova E., Roumiantseva J., Illarionova O., Lagoyko S., Miakova N., Zerkalenkova E., et al. Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children. Br J Haematol 2022; 196 (1): e6–9.56. Huang Y.J., Coustan-Smith E., Kao H.W., Liu H.C., Chen S.H., Hsiao C.C., et al. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes. J Formos Med Assoc 2017; 116 (10): 774–81.Huang Y.J., Coustan-Smith E., Kao H.W., Liu H.C., Chen S.H., Hsiao C.C., et al. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes. J Formos Med Assoc 2017; 116 (10): 774–81.57. Gaipa G., Cazzaniga G., Valsecchi M.G., Panzer-Grumayer R., Buldini B., Silvestri D., et al. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica 2012; 97 (10): 1582–93.Gaipa G., Cazzaniga G., Valsecchi M.G., Panzer-Grumayer R., Buldini B., Silvestri D., et al. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica 2012; 97 (10): 1582–93.58. Buldini B., Maurer-Granofszky M., Varotto E., Dworzak M.N. Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies. Front Pediatr 2019; 7: 412.Buldini B., Maurer-Granofszky M., Varotto E., Dworzak M.N. Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies. Front Pediatr 2019; 7: 412.